leadf
logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics completes $25.2 million capital raising

The company’s investigational new drug paxalisib is being developed to treat glioblastoma (GBM), an aggressive type of brain cancer, and other cancers.

Kazia Therapeutics Ltd - Kazia Therapeutics completes $25.2 million capital raising
Kazia has moved onto a pivotal study for paxalisib in glioblastoma

Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has successfully completed the A$8.8 million retail component of its A$25.2 million entitlement offer of shares at 80 cents per new share.

Earlier this month, Kazia had raised A$16.4 million via the institutional component of the one-for-three entitlement offer.

Kazia will use the proceeds to fund its participation in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), the pivotal study for registration of paxalisib in glioblastoma.

The company’s investigational new drug paxalisib is being developed to treat glioblastoma (GBM), an aggressive brain cancer, and other types of cancers.

“Final stage of the drug development process”

Kazia chairman Iain Ross said “As always, we are grateful for the support of our shareholders as the company moves forward.

“This next chapter in the company’s development should be an exciting and rewarding period, and we have been pleased to have been able to provide this opportunity for shareholders to strengthen their positions.

“We now move into the pivotal study for paxalisib in glioblastoma, placing us in the final stage of the drug development process and on a direct path to commercialization.”

Quick facts: Kazia Therapeutics Ltd

Price: 1.37 AUD

ASX:KZA
Market: ASX
Market Cap: $129.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics moves into operational phase of pivotal study for...

Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott soon after announcing they've executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to begin participation in the GBM AGILE pivotal study in glioblastoma. The study is set to open...

on 21/10/20

2 min read